These cloud data companies are uniquely positioned to create value and reward investors in the long run. Read More...
Motley Fool
Should You Buy This Under-the-Radar Growth Stock?
Earlier this month, AngioDynamics shared its financial results for the fourth quarter ended May 31. The Latham, New York-based medical device company topped both the analyst consensus for net sales and non-GAAP (adjusted) diluted earnings per share (EPS) in the quarter. AngioDynamics reported $87 million in net sales during the fourth quarter, which is equivalent to a 13.2% growth rate over the year-ago period.
Add Comment